Nahdi Stock Trading: A Comprehensive Guide to Analyzing the Share on the Saudi

Founded in 1986, Nahdi Medical Company has grown to become one of the largest and most important pharmacy chains in Saudi Arabia. Nahdi operates an extensive network of over a thousand branches across the country, giving it a strong presence nationwide. The company’s core business is the retail of pharmaceuticals, medical products, health and beauty items, as well as offering certain healthcare services such as pharmacy consultations and preventive screenings. Nahdi was listed on the Saudi financial market (Tadawul) under the symbol 4164, quickly becoming a prominent player in the healthcare sector. The company stands out for its strong brand, high-quality services, and widespread reach, which have helped build a large customer base and investor confidence. Nahdi provides regular financial reports and disclosures via its official website and investor relations section, enabling shareholders and the public to track the latest developments and financial performance. This transparency and ease of access to information help attract further attention from market participants. Today, Nahdi’s stock is considered one of the most important in the Saudi healthcare sector and is viewed as an indicator of the health and growth of this vital industry.

Nahdi stock saw notable movements in 2024 and 2025, impacting its market value and attracting investor attention. Key recent indicators include:

- Share Price: The average share price was around SAR 99.65 in mid-2025, after having reached higher levels in previous periods.
- Market Capitalization: Ranged between SAR 30 and 35 billion, based on the share price and approximately 316 million outstanding shares.
- Price-to-Earnings Ratio (P/E): Ranged between 25 and 35 times, which is relatively high compared to the market average but reflects positive expectations for earnings growth.
- Cash Dividends: Nahdi distributed partial dividends exceeding 2% of capital during 2023 and 2024, and continues to review its future dividend policy for greater clarity.

These indicators are available through quarterly and annual reports published on the company’s website and the Tadawul platform. It is always advisable to follow periodic updates for real-time information on the share price and performance.

Since its listing on the Saudi financial market, Nahdi has experienced fluctuations in its share price. The stock peaked at SAR 150–160 in mid-2023 before declining to around SAR 100 in early 2025. This relative drop was also reflected in the company’s market capitalization, which decreased from its peak but remained among the largest in the pharmacy sector.

Share price is influenced by several factors, including quarterly results, dividend announcements, changes in the healthcare sector, and overall market performance. It is important to note that the share price is not fixed and changes daily based on supply and demand, which can be tracked via official Tadawul platforms or Nahdi’s investor relations site.

Market capitalization is calculated by multiplying the share price by the number of outstanding shares and is a key indicator of the company’s size and market strength. Despite fluctuations, Nahdi has maintained a strong position in the Saudi market, and its share performance continues to reflect developments in the local healthcare sector.

The price-to-earnings ratio (P/E) is a key financial metric used by investors to evaluate Nahdi stock. At the end of 2024, the P/E ranged between 25 and 35 times, above the general market average, but indicative of positive expectations for earnings growth and sustained demand in the healthcare sector.

Regarding cash dividends, Nahdi has announced several distributions since its listing, with payout ratios ranging from 2% to 5% of capital in certain periods. However, the company has not yet set a fixed annual dividend policy, preferring to review distributions periodically based on financial performance and available liquidity. Investors typically await official disclosures to learn about dividend amounts and timing, making this a key attraction for those seeking stable periodic returns.

The healthcare and pharmacy sector in Saudi Arabia is experiencing rapid growth, driven by increased health spending and demographic expansion. Vision 2030 aims to boost investment in healthcare and improve service quality, supporting the growth of companies like Nahdi.

The sector features a diverse value chain: from pharmaceutical manufacturing and distribution to retail sales in pharmacies. Large pharmacy chains like Nahdi are particularly important for their ability to offer comprehensive services, negotiate favorable prices with suppliers, and leverage their widespread presence.

Companies in this sector face challenges such as intense competition, regulatory changes, and drug pricing pressures. Nevertheless, ongoing demand for health products and the expansion of mandatory health insurance continue to support the sector and create opportunities for growth and expansion.

Despite its leadership in the pharmacy sector, Nahdi faces strong competition from several sources:

- Other major pharmacy chains such as Dawaa Pharmacies, Al-Dhila Pharmacy, and Tadawe Group, each with extensive networks.
- Online sales platforms and digital pharmacies that enable ordering and delivery of medicines via apps, targeting younger and digitally savvy consumers.
- Large pharmaceutical distribution companies that indirectly impact the market by supplying medicines to pharmacies.
- Local startups and initiatives offering new or specialized pharmacy services.

Nahdi maintains a high competitive edge thanks to its geographic reach, trusted brand, and pricing strategies supported by its logistics centers. However, like other companies, it must continuously innovate to maintain its market share amid technological and behavioral shifts among customers.

Studies indicate that the Saudi pharmaceuticals and pharmacy market is expected to grow annually by over 6% in the coming years, driven by rising local demand, expanded health insurance, and increased chronic diseases. This growth presents significant opportunities for companies like Nahdi to expand their customer base and boost revenues.

On the other hand, the sector faces regulatory challenges, with the Saudi Food and Drug Authority closely monitoring sales and distribution and frequently updating regulations. These may include new pharmacy licensing requirements, drug pricing policies, or compliance with local health standards. Any regulatory changes can directly impact company profits and margins, so Nahdi and other sector players closely monitor regulatory developments to ensure compliance and mitigate risks.

Nahdi is adopting digital transformation strategies to keep pace with sector developments and meet growing customer demands. These strategies include developing electronic applications for ordering and delivering medicines, digital pharmacy consultations, and digital loyalty programs to strengthen customer relationships.

In 2024 and 2025, Nahdi launched several digital initiatives, such as a virtual pharmacist service and electronic invoice management. The company also introduced advanced payment options and user-friendly digital interfaces. This transformation enhances internal operational efficiency and provides customers with a seamless, modern experience.

Nahdi also aligns with the Saudi government’s push for healthcare digitization, such as the implementation of electronic patient records and e-prescriptions, reinforcing its position as an innovator in the field.

As part of its growth strategy, Nahdi continued to open new branches across the Kingdom during 2024 and 2025, further strengthening its geographic presence. The company also signed several cooperation agreements and memoranda of understanding with entities in the healthcare sector, including health insurance companies and medical and technology service providers.

These partnerships aim to deliver integrated healthcare services, such as mini health centers within certain branches and streamlined prescription fulfillment through its network in collaboration with insurers. Additionally, Nahdi expanded its digital activities by partnering with health tech companies to develop its electronic services.

This strategy enhances Nahdi’s competitiveness and opens up new revenue streams, positively impacting share performance and investor confidence.

Nahdi delivered strong financial performance in its quarterly results for 2024 and 2025. For example, the company achieved net profit growth exceeding 20% in Q1 2025 compared to the previous year, driven by increased sales and improved profit margins.

These results demonstrate the company’s ability to adapt to market changes and successfully expand its customer base. Annual reports also showed higher revenues and operating profit growth, providing a solid financial foundation for further expansion and investment.

Investors closely follow these results via the company’s official website or specialized financial news platforms, as they represent a key indicator of the share’s strength and stability in the market.

Nahdi stock has experienced notable volatility on the Tadawul platform over the past two years. The share saw significant gains following strong financial results or news of strategic partnerships, such as in early 2025 when it rose by more than 7% in a single trading day.

Conversely, the stock faced periods of decline due to global market movements or shifts in investor sentiment. These fluctuations reflect the dynamic nature of the stock market, where prices react to news, financial results, and sector and company growth expectations.

Therefore, it is always advisable to monitor company news and financial reports published on its official website and trading platforms to track the latest share movements and understand their causes.

Nahdi’s share price is influenced by several key factors:

- Quarterly and annual company results: Any growth in profits or revenues typically has a positive impact on the share price.
- Regulatory changes in the healthcare sector: Such as updated regulations or drug pricing policies.
- General economic developments: Oil prices, local and global economic performance.
- Rumors and media news: Including partnership announcements, expansions, or management changes.
- Competitor performance: Strategic moves by competitors can affect investor evaluations of Nahdi’s stock.

These factors interact to determine the share’s direction in both the short and long term. It is important for investors to continuously monitor news and financial indicators to understand share movements and their rationale.

Like all listed stocks, investing in Nahdi carries several risks that should be carefully considered:

- General market volatility, which can negatively impact the share price regardless of company performance.
- Intense competition in the pharmacy sector, potentially affecting profit margins and market share.
- Sudden changes in regulations or pharmaceutical insurance policies.
- Technological shifts that may challenge companies unable to keep pace.
- Unforeseen events such as pandemics or economic crises that could affect demand.

Investors are always advised to conduct thorough risk analysis and not make investment decisions without comprehensive study and consultation with a licensed financial advisor.

To track Nahdi’s share price, several tools are available:

- The official Saudi financial market (Tadawul) website, which provides prices, trading volumes, and daily and historical data for the stock.
- Nahdi’s official website, investor relations section, offering real-time data and share movement information.
- Financial news platforms such as Argaam, Bloomberg, and Sahm Capital.

To purchase the stock, investors must open a trading account with a licensed brokerage in Saudi Arabia. After completing identity requirements and activating the account, buy or sell orders can be placed during official trading sessions. The system allows purchases starting from a single share, and it is advisable to follow daily news and market analysis before making any buying decisions.